Cargando…
Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors
BACKGROUND: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766694/ https://www.ncbi.nlm.nih.gov/pubmed/23981813 http://dx.doi.org/10.1186/1477-7525-11-145 |
_version_ | 1782477313037828096 |
---|---|
author | Shin, Yong Soon Kim, Jeong Hoon |
author_facet | Shin, Yong Soon Kim, Jeong Hoon |
author_sort | Shin, Yong Soon |
collection | PubMed |
description | BACKGROUND: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire is, overall, a valid instrument to assess the health-related quality of life in Korean cancer patients, although its reliability and validity have not yet been evaluated in patients with brain tumors. This study aimed at evaluating the psychometric properties of these instruments in patients with brain tumors. FINDINGS: The 2 instruments were used for 307 Korean patients with brain tumors. Multi-trait scaling confirmed the scale structure of the instruments with good item convergent and discriminant validity. The reliability was acceptable for all scales except for cognitive functioning and nausea and vomiting. The instruments could be used to distinguish between clinically distinct groups of patients. CONCLUSIONS: The study findings indicate that the instruments are valid and suitable for the assessment of the health-related quality of life in patients with brain tumors as well as in those with primary brain cancer. |
format | Online Article Text |
id | pubmed-3766694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37666942013-09-09 Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors Shin, Yong Soon Kim, Jeong Hoon Health Qual Life Outcomes Short Report BACKGROUND: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire is, overall, a valid instrument to assess the health-related quality of life in Korean cancer patients, although its reliability and validity have not yet been evaluated in patients with brain tumors. This study aimed at evaluating the psychometric properties of these instruments in patients with brain tumors. FINDINGS: The 2 instruments were used for 307 Korean patients with brain tumors. Multi-trait scaling confirmed the scale structure of the instruments with good item convergent and discriminant validity. The reliability was acceptable for all scales except for cognitive functioning and nausea and vomiting. The instruments could be used to distinguish between clinically distinct groups of patients. CONCLUSIONS: The study findings indicate that the instruments are valid and suitable for the assessment of the health-related quality of life in patients with brain tumors as well as in those with primary brain cancer. BioMed Central 2013-08-27 /pmc/articles/PMC3766694/ /pubmed/23981813 http://dx.doi.org/10.1186/1477-7525-11-145 Text en Copyright © 2013 Shin and Kim; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Report Shin, Yong Soon Kim, Jeong Hoon Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors |
title | Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors |
title_full | Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors |
title_fullStr | Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors |
title_full_unstemmed | Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors |
title_short | Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors |
title_sort | validation of the korean version of the european organization for research and treatment of cancer brain cancer module (eortc qlq-bn20) in patients with brain tumors |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766694/ https://www.ncbi.nlm.nih.gov/pubmed/23981813 http://dx.doi.org/10.1186/1477-7525-11-145 |
work_keys_str_mv | AT shinyongsoon validationofthekoreanversionoftheeuropeanorganizationforresearchandtreatmentofcancerbraincancermoduleeortcqlqbn20inpatientswithbraintumors AT kimjeonghoon validationofthekoreanversionoftheeuropeanorganizationforresearchandtreatmentofcancerbraincancermoduleeortcqlqbn20inpatientswithbraintumors |